NCT07405164 2026-04-17
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
11 trialsNCT05012371 2026-03-05
Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
NCT02184416 2026-02-27
ADONIS
Pfizer
Completed
NCT02811861 2026-02-23
CLEAR
Eisai Inc.
Phase 3 Active not recruiting
NCT01217931 2026-01-30
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07369505 2026-01-27
Sapu003 in Advanced mTOR-sensitive Solid Tumors
SAPU NANO (US) LLC
Phase 1 Recruiting
NCT01120249 2025-09-16
S0931
SWOG Cancer Research Network
Phase 3 Completed
NCT01313559 2025-04-30
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT04195750 2025-04-29
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03324373 2025-04-24
Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
University of Iowa
Phase 1 Completed